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In recent years, semen quality and fertility in aging male have received in-
creasing attention for several reasons. First, there is a trend in developed 
countries toward higher paternal (and maternal) age, predominantly due to 
socioeconomic factors. Family planning often begins after the pursuit of edu-
cation and establishment of professional career, resulting in higher paternal age. 
Moreover, divorce, remarriage, and the wish to be a father of child(ren) in a 
new partnership are increasing trends. Secondly, recent improvements in 
assisted reproduction technology, particularly in vitro fertilisation and intracyto-
plasmic sperm injection, have enabled males and couples who were previously 
considered infertile to produce genetic offspring (Jungwirth et al., 2013). 
At the same time, the accumulation of several factors and conditions occurs 
along with aging that may affect male reproductive function. There are some 
reports on the impacts of paternal occupation on seminal function (Kenkel et 
al., 2001; Magnusdottir et al., 2005). Also, vascular, hormonal, metabolic and 
malignant diseases, injuries, lifestyle-related conditions and accumulation of 
toxic substances may alter reproductive function. 
Thus, male aging is a multifactorial process that causes changes in different 
reproductive organs, including the prostate. The prostate, an accessory gland of 
the male reproductive system, is directly related to male reproductive, sexual, 
and ejaculatory functions (McVary, 2006; Hellstrom et al., 2009, Gacci et al., 
2011). Although benign prostatic hyperplasia (BPH), a progressive condition 
characterized by prostate enlargement and lower urinary tract symptoms 
(LUTS), is uncommon before 40 years of age, roughly 50% of men develop 
BPH-related symptoms by 50 years. The incidence of BPH increases by 10% 
per decade and reaches 80% by 80 years of age (Oelke et al., 2013). In addition, 
recent studies have described the risks of prostatitis, male accessory gland 
infections and prostate cancer in middle-aged infertile males (Rolf et al., 2002; 
Ruhayel et al., 2010; Walsh et al., 2010; Ng et al., 2004). However, little is 
known about the associations between reproductive function and prostate 
pathologies in males over 45 years. Moreover, middle-aged males have been 
generally underrepresented in clinical studies and data on reproductive function 
in healthy and infertile males over 45 years are limited (Stewart, Kim, 2011; 
Sartorius, Nieschlag, 2010). Also, only few published studies have examined 
hormonal status or potential confounders in men over 45 years of age (Merino 
et al., 1995; Arai et al., 1998; Pasquallato et al., 2005; Hellstrom et al., 2006). 
Therefore, the main aims of this work were to specify reproductive function 
in middle-aged males (age 45 to 69 years), and to find out possible influences of 
different prostate conditions and lifestyle-related factors on male reproduction. 




1. Male reproductive tract 
1.1. Anatomy 
The male reproductive system consists of primary reproductive organs, testicles, 
and the secondary reproductive organs, the scrotum, urethra, prostate gland, 
penis, bilateral epididymides, ductus deferenses, seminal vesicles, and bulbou-
rethral glands (Figure 1). Testicles are located outside the body cavity in the 
scrotum, and contain seminiferous tubules surrounded by tunica albuginea and 
hormone-producing Leydig cells as interstices between the tubules. The testicle 
is divided into 250 to 300 lobules, each containing 1–3 seminiferous tubules. 
Sertoli cells that support sperm production in adult male are located on the basal 
membrane of tubules. 
After spermatogenesis, newly formed sperm cells are transported from the 
testicles to the epididymis on the external surface of each testicle, and then 
through the ductus deferens into the pelvic cavity. The ductus deferens joins the 
ducts of the seminal vesicles, the glands located next to the ampulla of the 
ductus deferens, and forms the ejaculatory duct,  surrounded by the walnut-size 
prostate gland, and empties into the urethra. The urethra exits from the pelvis 








The male reproductive system depends on hormonal, sperm-producing, and 
neural mechanisms (Seeley et al., 1999; Nieschlag, Behre, 2010). Neural 
mechanisms are primarily involved in controlling ejaculatory and urinary 
function, and expressing sexual acts and behaviours. Hormonal mechanisms 
that influence the male reproductive system involve the hypothalamus and 
pituitary gland in the central nerve system and the testicles. The main hormonal 
functions are described in chapter 2.2. 
Spermatogenesis starts with stem cells division and ends with the maturation 
of sperm cells, including mitotic proliferation, meiotic division and trans-
formation of haploid germ cells (spermatids) into sperms (Nieschlag, Behre, 
2010). Sperm cells from testicles and secretions from reproductive glands form 
semen as the main product of the male reproductive tract. The seminal vesicles 
produce about 60%, the prostate gland approximately 30%, and the testicles, 
epididymides and bulbourethral glands account for approximately 10% of 
seminal fluid (Seeley et al., 1999; Nieschlag, Behre, 2010). The main as-




2. Male reproductive function 
2.1. Semen quality 
Semen analysis is the basis of assessments of male reproductive function. 
Ejaculate analysis and lower reference limits for semen parameters have been 
standardised by the World Health Organization (WHO) Laboratory Manual for 
the Examination and Processing of Human Semen (WHO, 2011) and are 
described in Table 1.  
 
 
Table 1. Lower reference limits (5th centiles and their 95% Confidence Intervals, CIs) 
for main semen characteristics (WHO, 2011). 
Parameter Lower reference limit 
Semen volume (mL)                                              1.5 (1.4–1.7) 
Total sperm number (106/ejaculate)                    39 (33–46) 
Sperm concentration (106/mL)                             15 (12–16) 
Total motility (%) 40 (38–42) 
Progressive motility (%)                                        32 (31–34) 





According to the WHO (2011), oligozoospermia is characterised by a total 
sperm number less than 39 × 106 or sperm concentration less than 15 × 106/mL, 
asthenozoospermia with less than 32% progressively motile spermatozoa, and 
teratozoospermia with normal morphological forms of sperms below 4% in 
ejaculate (WHO, 2011; Jungwirth et al., 2013). 
If the results of semen analysis are normal according to WHO criteria, then 
one test is considered sufficient to determine male seminal function. If the 
results of semen analyses are abnormal in at least two tests, further andrological 
investigations are indicated (Jungwirth et al., 2013). 
Semen has two major quantifiable attributes, total number of spermatozoa 
and fluid volume. The number of spermatozoa reflects sperm production by the 
testicles and the patency of the post-testicular duct system, whereas the fluid 
volume contributes to the function of accessory glands and their secretory acti-
vities (WHO, 2011). During ejaculation, semen is produced from a concentrated 
suspension of spermatozoa, stored in paired epididymides, mixed and diluted by 
fluid secretions from the accessory sex organs. Semen quality depends on 
factors that usually cannot be modified, such as sperm production by the 
testicles, secretions of male accessory glands and recent (particularly febrile) 
illness, as well as other factors, such as abstinence time before the semen 
analysis, that should be recorded and taken into account in the interpretation of 
results. Semen quality also depends on collection of complete/ incomplete 
semen sample and the size of the testicles (WHO, 2011).  
 
 
2.2. Reproductive hormones 
The major male hormone, testosterone, is secreted in the testicles (Figure 2) and 
is responsible for the differentiation of male genitals and reproductive system, 
spermatogenesis and secondary sexual characteristics. Testosterone may exert 
its effects directly, or after its metabolism to dihydrotestosterone or estradiol 
(E2).  
Testicular function is regulated by luteinizing hormone (LH) activating the 
interstitial Leydig cells in the testicles to produce testosterone, and by follicle-
stimulating hormone (FSH) promoting spermatogenesis via testicular Sertoli 
cells. Release and production of the LH and FSH in the hypophysis are 























































































































































































Hormonal alterations of the hypothalamic-pituitary-testicular (HPT) axis are 
well-accepted, although they are not common causes of male infertility. Even 
though serum gonadotropin levels could be variable because of pulsatile 
secretion, a single measurement is usually sufficient to determine a patient’s 
clinical endocrine status. An accurate endocrine evaluation should be performed 
if there is: (1) an abnormal semen analysis, especially if the sperm concentration 
is less than 10 x 106/ml; (2) impaired sexual function; or (3) other clinical 
findings suggestive of a specific endocrinopathy  (Jarow et al., 2011; Jungwirth 
et al., 2013). 
 
 
2.3. Associations between reproductive function and prostate 
A healthy human prostate is slightly larger than a walnut. The mean weight of a 
"normal" prostate from an adult male is approximately 15 to 25 grams. It 
surrounds the urethra just below the urinary bladder and can be felt during a 
digital rectal examination. The prostate can be divided in two ways: by lobes 
(anterior, posterior, lateral and median) or by zones (Figure 3). It does not have 
a capsule; rather, it is surrounded by an integral fibromuscular tissue and 
sheathed by the pelvic floor muscles, which contract during ejaculation.  The 
prostate plays a role in male seminal function and the gland is the main source 
of prostate-specific antigen (PSA), zinc, citric acid and prostatic acid phospha-
tase (Elzanaty et al., 2002; Sampson et al., 2007; Nieschlag, Behre, 2010). 
 
 
Figure 3. Anatomical position of prostate zones (a, transitional zone; b, periurethral 




Prostatic fluid is expelled in the first ejaculate fraction with most of the sper-
matozoa. Compared to the few spermatozoa that are expelled with the seminal 
vesicular fluid, those expelled in prostatic fluid have better motility and survive 
longer. Associations between reproductive function and different prostate 
conditions have been discussed in chapter 3.2.1. 
 
 
3. Age-related changes in male organism 
Aging commonly is a normal physiological process that involves morphological 
and functional changes within organs and tissues, accompanied by impairment 
of certain functions and increased susceptibility to age-related diseases. 
Although there are no specific aging diseases, the incidence of chronic diseases 
increases with age (Nieschlag, Behre, 2010). 
Known alterations in the aging male involve several organ and regulatory 
systems, such as the endocrinological and cardiovascular systems, lipid and 
bone metabolism, and genitourinary tract function. Reductions of growth hor-
mone, dehydroepiandrosterone, dehydroepiandrosterone sulphate, melatonin, 
thyroid-stimulating hormone, triiodothyronine, thyroxine, and hyperinsulinemia 
also occur in older males (Nieschlag, Behre, 2010).   
 
 
3.1. Impact of aging on male reproductive function  
Like other processes in the human body, aging of the male reproductive tract is 
accompanied by multifactorial changes at the molecular, cellular and regulatory 
levels (Kirkwood, 2005). These changes affect various levels of the HPT axis, 
leading to changes in circulating androgen levels and later effects in androgenic 
organs. Although the roles of gonadotropins and androgens on spermatogenesis 
are well-established, the impacts of a secondary decrease in androgen levels on 
spermatogenesis and fertility are still unclear (Sartorius, Nieschlag, 2010). Also, 
the proportion of sex-hormone binding globulin (SHBG) increases, whereas 
bioactive free testosterone decreases, in older male (Nieschlag, Behre, 2010). 
Evidence from clinical studies suggests that age is associated with di-
minished semen volume, sperm motility, and sperm morphology, but sperm 
concentration is little affected by age (Kidd et al., 2001; Kuhnert, Nieschlag, 
2004; Sartorius, Nieschlag, 2010; Harris et al., 2011). Methodologically 
stronger studies have shown that semen volume decreases 3%–22%, sperm 
motility 3%–37%, and percent of normal sperms 4%–18%, comparing 30- to 
50-year-old men (Kidd et al., 2001). Considering the WHO reference ranges 
(WHO, 1999), a study by Ng et al. (2004) showed that semen volume, sperm 
concentration and total sperm count were subnormal in 20%, 22% and 22%, 
respectively, of men at 52 to 79 years of age. Among the subjects in younger 
group (age <52 years), comparable figures were 20%, 6.5% and 6.9%, respec-
tively. The proportion of men with completely normal semen analysis (semen 
volume, sperm concentration and total sperm count above reference ranges) was 
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significantly lower among older men (30%) compared to younger men (72%). 
Moreover, Dunson et al. (2004) showed that seminal parameters start to decline 
after 35 years of age, resulting in reduced fertility and diminished fecundity a 
few years later (Kuhnert, Nieschlag, 2004). 
In infertile couples, 20–30% of men have low testosterone level (Lombardo 
et al., 2005). The frequency of sexual activity per month for men decreases, on 
average, by 50% between 50 and 60 years of age, and another one to two times 
after age 60 years (Araujo et al., 2004).  Although reduced male sexual activity 
is more often related to psychological changes, the age-related decrease of 
sexuality may be an indirect reason for couple’s infertility (Shindel et al., 2008). 
However, the lack of correlation between semen parameters and serum testo-
sterone levels suggests that changes in spermatogenesis are not due to a loss of 
testicular steroidogenic potential.  
Testicle volume, a rough indicator of Sertoli cell number and spermatogenic 
potential (Harris et al., 2011), remains constant throughout life. Excluding men 
with diseases known to reduce testicular size, age reduces testicular volume 
only in the eighth decade of life or later. In healthy 80-year-old men, testicle 
volume was, on average, 20–31% lower compared to males under 40 years old 
(Handelsman, Staraj, 1985; Mahmoud et al., 2003).  
Aged testicles have reduced number of Leydig and germ cells, thickening of 
the basal membrane and defective vascularization of testicular parenchyma, 
including Sertoli cells (Dakouane et al., 2005). These changes might impair 
spermatogenesis and diminish feedback from the testicles to the pituitary gland, 
resulting in elevated serum FSH and LH levels. Higher serum FSH levels has 
been correlated with decreased sperm concentration, decreased sperm motility, 
and a decreased percentages of sperm with normal morphology, whereas higher 
serum LH level was correlated with decreased sperm concentration (Sartorius, 
Nieschlag, 2010).   
There are no longitudinal studies evaluating the effect of aging on various 
aspects of reproductive function, and guidelines for evaluating older fathers 
have not been developed (Stewart, Kim, 2011). Men older than 50 years have 
been underrepresented in clinical studies, and limited statistical power has 
prevented the determination of the shape of the relationship between age and 
semen quality. The main changes in the aging male reproductive tract are 




Figure 4. Main alterations of the aging male reproductive tract. 
 
 
3.2. Causes for alterations in the aging male reproductive tract   
Age-dependent alterations of semen parameters may have several causes. In 
addition to age per se, factors such like injuries, accumulation of toxic sub-
stances, vascular, hormonal and metabolic diseases, and anatomical or physio-
logical conditions may be responsible for  deterioration of semen parameters.  
 
 
3.2.1. Prostate pathologies 
Previous reports have revealed changes in the prostate of the aging male, such 
as smooth muscle atrophy and a decrease in protein and water content, that may 
contribute to decreased semen volume and sperm motility (Kuhnert, Nieschlag, 
2004). 
Well-known pathological conditions of prostate include prostate inflam-
mation, BPH and prostate cancer (PCa). These age-dependent prostate alte-
rations are detectable histologically in 50% of 50-year-old and 80% of 80-year-
old men (Hermann et al., 2000). PCa, the most common non-cutaneous 
malignancy in men of Western countries, is strongly associated with age. BPH, 
prostatic intraepithelial neoplasia (PIN) as the premalignant and -invasive stage 
of prostatic adenocarcinoma and PCa have been identified as sequelae of 
chronic intraprostatic inflammation (Nelson et al., 2004; Kramer, Marberger, 
2006; Heidenreich et al., 2013). 
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3.2.1.1. Prostate inflammation 
Prostate inflammation (prostatitis) is a common condition being one of the most 
frequent urologic diseases in men (Engeler et al., 2006). According to National 
Institute of Health classification (Krieger et al., 1999), prostatitis occurs in four 
forms: 1) acute bacterial prostatitis, 2) chronic bacterial prostatitis (CBP), 3) 
chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS) and 4) 
asymptomatic prostatitis. Studies of semen quality have been carried out mainly 
in younger males, and therefore associations between the prostate inflammation 
and reproductive function in aging males are underinvestigated. Also, one of the 
most important drawback of the topic is lack of age-matched controls (Engeler 
et al., 2006). 
Male infertility and altered seminal function may be one of the most serious 
consequences of CBP and CP. Potential mechanisms include obstruction of 
male genital tract, alterations in the prostate’s biochemical environment, 
formation of reactive oxidative species (ROS), and leukocyte infiltration. 
Leukocytospermia and ROS have been associated with infertility and alterations 
in seminal parameters, such as sperm count, motility and morphology (Schoor, 
2002; Menkveld et al., 2003; Agarwal et al., 2006; Shi et al., 2012). Although 
unconfirmed, seminal leukocytes, produced predominantly in prostatic fluid, 
may provide the connection between ROS generation and impaired semen 
parameters (Schoor, 2002; Shi et al., 2012). There are several reasons why 
spermatozoa are more vulnerable to ROS than other cells. First, the sperm 
membrane contains a high level of polyunsaturated fatty acids with susception 
of peroxidation. Peroxidative damage may result in loss of membrane functions 
and may lead to a reduction in fertilizing ability, motility and viability. Se-
condly, in contrast to other cells, spermatozoa have very limited ability to repair 
damaged structures, as a consequence of their small amount of cytoplasm and 
an active, highly condensed chromatin. Third, spermatozoa are equipped with a 
poor defence system against ROS; catalase is absent, and glutathione peroxidase 
and superoxide dismutase are present in relatively low amounts (Dohle, 2003).  
To our best knowledge, only one retrospective cross-sectional study showing 
that genital tract infection may be a risk factor for semen quality in aging males 
has been published (Rolf et al., 2002). Infections of accessory glands were 
determined by positive bacteriological aerobic and⁄or anaerobic culture, 
screening for immunoglobulin A antibodies against chlamydia in seminal 
plasma, indicating an acute chlamydia infection, or leukocytospermia (>1.0 x 
106 leukocytes/mL) in combination with at least two other indirect signs of 
infection of the accessory glands, such as abnormal viscosity, elevated pH, or 
hypospermia. Data of more than 3,500 infertile men demonstrated that 
accessory glands inflammation occured in 6.1% of men under 25 years and 
13.6% of patients over 40 years. Total sperm counts and semen volume were 
significantly lower in infertile subjects with infected accessory glands compared 
to men with idiopathic infertility. As ejaculate volume declined significantly in 
subjects with infections, but testicular volume remained unchanged, the post-
testicular origin of impaired sperm count and semen volume, most probably due 
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to partial occlusion of the efferent ducts, must be considered causative. In 
addition, the proportion of subjects with infection increased with advancing age, 
providing more evidence that infertility is acquired due to infection, at least in 
some patients (Rolf et al., 2002). 
 
3.2.1.2. Prostate cancer 
Only one previous study has investigated possible relations between semen 
quality and prostate cancer. In that study, 26 older men with histologically con-
firmed, organ-confined prostate cancer did not have altered seminal parameters 
compared to remaining 27 age-matched men without evidence of prostate 
cancer on biopsy (Ng et al., 2004). 
 
3.2.1.3. Benign prostate hyperplasia  
Although we have prior scientific evidence associating LUTS, prostate 
enlargement and male reproductive functions, including erectile and ejaculatory 
dysfunction (McVary, 2006; Hellstrom et al., 2009, Gacci et al., 2011), there 
are currently no data associating LUTS and/or BPH with male seminal tract 
function and associated reproductive indicators (to our best knowledge). 
 
 
3.2.2. Other chronic genital tract diseases 
Increasing evidence suggests that chronic inflammatory conditions of the male 
genital tract (testicles, epididymis, and seminal vesicles) may not only impair 
basic sperm parameters, but also sperm functions and, subsequently, outcomes 
of in vitro fertilisation/intracytoplasmic sperm injection treatments. However, 
data showing that these diseases have negative influences on sperm quality and 
male fertility in general are controversial (Jungwirth et al., 2013). Also, the 
relations between chronic testicular inflammation and male infertility are under-
investigated (Schuppe et al., 2010). 
There are several pathophysiological mechanisms that may impair sperm 
function, including reduced accessory gland function, obstruction of sperm 
transport, the presence of unsuitable microenvironment in male genital tract, 
and dysregulation of spermatogenesis (La Vignera et al., 2011, 2014). For 
example, ROS and cytokines, products of neutrophil infiltration during in-
fection, have roles defending against exogenous microorganisms, but may also 
contribute to tissue damage (Meinhardt, Hedger, 2011), seminal plasma hyper-
viscosity (Aydemir et al., 2008), and/or sperm dysfunction (Lampiao, du 
Plessis, 2009; Kullisaar et al., 2013) in infertile males. 
Inflammation of the male genitourinary tract is a possible risk factor for im-
paired semen quality, and may affect sperm parameters to various extents, 
depending on the location in male reproductive tract. Moreover, different 
infectious agents may alter male accessory gland functions via inflammation 
(Mahmoud et al., 1998) and secondary obstruction (Dohle, 2003). These 
obstructions are usually incomplete and cause poor sperm quality, including low 
semen volume. Also, obstruction may cause epididymal occlusion, as well as 
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enlargement and cystic lesions of seminal vesicles, epididymis and prostate 
(Dohle, 2003). 
Inflammation of the epididymis (epididymitis) in sexually active men under 
35 years is most often caused by Chlamydia trachomatis or Neisseria gonorr-
hoeae. Nonsexually transmitted epididymitis is associated with urinary tract 
infection and occurs more often in men aged > 35 years, who have recently 
undergone urinary tract instrumentation or surgery, and in subjects with anato-
mical abnormalities (Jungwirth et al., 2013). Age-dependent, post-inflammatory 
alterations of the epididymis may lead to (partial) obstruction (Harris et al., 
2011).  
Also, the arteriographic impairments in the epididymis are correlated with 
systemic arteriosclerosis and may be age-related (Regadera et al., 1985). Epi-
didymal alterations of various origins may lead to disturbed mitochondrial 
function and sperm dysmaturation (Aitken et al., 2007), giving possible expla-
nation how sperm motility might be affected in older male.   
 
 
3.2.3. Tumours and traumas in pelvic area  
Malignant diseases may impair gonadal functions through hormonal alterations 
and metabolic conditions. Decreased reproductive hormones in cancer patients 
could result from stress, downregulation of endocrine substances produced by 
some tumours, or as a consequence of a metabolic condition. For example, in 
leukemia, lymphoma, and central nervous system tumours, the hypothalamus 
and the pituitary gland function may be directly impaired by tumour cell 
invasion or radiation therapy. Malignancies may also produce gonadal 
dysfunction via vitamin, mineral and/or trace element deficiencies. Moreover, 
tumour-released cytokines may affect spermatozoa, resulting in sperm 
alterations (Dohle, 2010). The main prognostic determinants of posttreatment 
fertility are the localisation of neoplasm and pretreatment semen quality 
(Trottmann et al., 2007).   
Main sources of cancer in male genital tract are prostate and testicle(s). 
Associations between reproductive function and prostate cancer have been 
discussed in chapter 3.2.1. 
Testicular germ cell tumour (TGCT), the most common malignancy in white 
men aged 15 to 40 years, affects approximately 1% of sub-fertile men. Testi-
cular cancer represents 1% to 1.5% of male neoplasms and 5% of urological 
tumours in general. The incidence in Western countries is approximately 3–10 
new cases in each year per 100,000 males, and varies between ethnic groups 
and countries. In the last 30 years, almost all Western countries have reported 
an increased incidence of testicular cancer. Epidemiological risk factors for  
testicular tumour development include prior infertility, history of cryptor-
chidism or undescended testicles (testicular dysgenesis syndrome), Klinefelter’s 
syndrome, familial history of testicular tumours, and the presence of a 
contralateral tumour or testicular intraepithelial neoplasia (Albers et al., 2013; 
Jungwirth et al., 2013). Men with TGCT have decreased semen quality, even 
21 
before cancer is diagnosed (Petersen et al., 1999). Moreover, surgical treatment 
of TGCT results in additional impairment of semen quality (Jungwirth et al., 
2013).  
Of all genito-urinary injuries, one-third to two-thirds involve the external 
genitalia. Genital traumas are more common between the ages of 15 and 40 
years. The main causes include road traffic accidents, physical sports, violent 
crime, and war-fighting (Summerton et al., 2013).  
Spinal cord injury, predominantly seen in young men, is commonly related 
to neurogenic reproductive dysfunctions, including abnormal semen charac-
teristics, ejaculatory failure and impotence. The causes are multifactorial and 
mainly post-testicular, including elevated oxidative stress, ROS and leukocyte 
levels in ejaculate, impairments in prostate and seminal vesicles milieu, 
postinjury bladder management, and autonomic nervous dysfunction, but all of 
them need further elucidation. Semen quality of men with spinal cord injury 
could impair as early as two weeks after injury. The main abnormality is seen in 
sperm motility not in sperm count (Patki et al., 2008). 
 
 
3.2.4. General diseases and age-related changes in lifestyle 
General diseases may eventually manifest in age-related health issues, including 
reproductive function, and may have a significant impact on the independence, 
general well-being and morbidity of men.  
The effects of geography, smoking, alcohol use, ethnicity, and body mass 
index (BMI) on semen volume or sperm parameters in aging men were in-
vestigated in a study by Hellstrom et al. (2006). According to this study, geo-
graphic regions affected only sperm motility. There were no differences in 
semen parameters between smokers and nonsmokers. Similarly, moderate 
alcohol consumption did not affect semen parameters in aging subjects. 
However, according to the study by Eskenazi et al. (2003), semen volume was 
higher in men who never used tobacco or who never consumed alcohol. 
Similarly, smoking has been associated with increased ROS in the male genital 
tract (Sharma, Agarwal, 1996) and oligozoospermia (Harris et al., 2011).  
The prevalences of obesity and metabolic syndrome (METS), the ever-
growing and leading health problems worldwide, are significantly higher in men 
with in- or subfertility compared to normal population (Kasturi et al., 2008). 
METS may decrease reproductive potential (Kasturi et al., 2008), including 
semen volume, sperm concentration and motility (Fejes et al., 2005a). More-
over, METS was shown to increase conversion of testosterone to estrogen 
through aromatase activity (Cohen, 2008), and may inhibit testosterone 
synthesis in testicles via chronic inflammation in the male genital tract (Kort et 
al., 2006). However, Hellstrom et al. (2006) found that BMI did not have 
significant effect on semen volume or other measured sperm parameters in men 
older than 45 years.  
Some previous reports indicated that paternal occupation (farming, metal 
working and painting) may affect seminal function (Kenkel et al., 2001; 
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Magnusdottir et al., 2005). Also, anti-spermatogenic effects of ionizing 
radiation are well documented. Doses as small as 20 Gy depressed sperm output 
from proliferating spermatogonia, and doses above 75 Gy caused azoospermia 
(Nieschlag, Behre, 2010).  
Possible links between mobile phones and semen parameters are detailed in 
few reports (Fejes et al., 2005b; Agarwal et al., 2008, Rago et al., 2013); 
however, the results in that topic are controversial and need additional research. 
Alterations in semen quality can also occur after exposure to toxic agents 
(Wyrobek, 1993). For example, many older men have been exposed to dichloro-
diphenyltrichloroethane and dibromochloropropane, endocrine disruptors that 
were used until 1970s (Kidd et al., 2001). Phthalates, nitroaromatic compounds 
and γ-diketones have been described as toxicants for seminal function 
(Nieschlag, Behre, 2010). Also, age-dependent increase of polychlorinated 
biphenyls was inversely correlated with sperm count and progressive motility in 
men with normal semen parameters (Dallinga et al., 2002). Among heavy 
metals, lead has been negatively associated with semen quality (Nieschlag, 
Behre, 2010). 
Several cross-sectional studies have focused on the effects of human 
immunodeficiency virus (HIV) on sperm parameters (Dulioust et al., 2002; 
Diehl et al., 2003; Nicopoullos et al., 2004; Pavili et al., 2010). The results are 
controversial, but differences between HIV-infected and noninfected men, 
mainly in sperm motility and morphology, have been demonstrated. Moreover, 
changes in semen quality with disease progression have been debated (Dulioust 
et al., 2002; van Leeuwen et al., 2008; Rusz et al., 2012). 
A study by Eskenazi et al. (2003) showed that sperm count and total number 
of progressively motile sperm were lower in men who had ever had high blood 
pressure. Some continuous medicines, including anti-hypertensives, H2 
blockers, anti-androgens, androgen replacement therapies, α1-blockers and 5-α-
reductase inhibitors, may affect semen quality (Harris et al., 2011; Stewart, 
Kim, 2011). Marijuana, cocaine and opiates have minimal effect on spermato-
genesis, but all narcotics could supress LH and testosterone secretion via 
inhibition of hypothalamic GnRH secretion (Nieschlag, Behre, 2010). Also, 
there is report that several chemotherapeutics have negative effect on spermato-




Hence, there are several unanswered questions concerning the factors that 
influene  reproductive function in middle-aged men. The possible roles of 
couple infertility status, environmental and lifestyle-related factors are under-
investigated. Moreover, associations between prostate conditions and male 
reproductive function are understudied and need additional studies. 
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AIMS OF THE RESEARCH 
The general aim of this work were was to specify reproductive function in 
middle-aged male and to find out possible influences of prostate conditions, 
lifestyle and couple’s infertility status on male reproduction. 
The specific aims of the research were: 
1) To compare the reproductive parameters in middle-aged healthy men and 
male partners of infertile couples; 
2) To discover the roles of lifestyle and education on reproductive function in 
middle-aged male;  
3) To determine possible role of male genital tract inflammation on repro-
ductive parameters in middle-aged male; 
4) To reveal the impacts of lower urinary tract symptoms and prostate enlarge-
ment on semen quality and associated reproductive indicators in middle-aged 
male; 
5) To evaluate reproductive function in male with premalignant and malignant 
prostate conditions; 
6) To detect possible association between reproductive function and prostate-













MATERIALS AND METHODS 
Table 2. Summary of study subjects. 
Study Subjects Investigations 
Reproductive 
function in middle-
aged healthy men 
versus male partners 
of infertile couples 
(Paper I) 
164 men with well-known status 
of couples infertility 
61 men who considered 
themselves healthy and had 
fathered at least one biological 
child 
Clinical investigation, basic 
semen analyses, blood 
samples for reproductive 
hormones, questionnaires 
about education, previous 
and current diseases, and 
lifestyle factors 
Reproductive 
function and semen 
quality in middle-







347 men with LUTS, CBP and/or 
CP/CPPS 
35 age-matched controls (without 
LUTS, CBP and/or CP/CPPS)  
Clinical investigation, basic 
semen analyses, seminal 
interleukin-6 (IL-6) and 
microbiological 
investigation, blood samples 
for reproductive hormones 
and PSA, uroflowmetry, 
ultrasound for total prostate 
volume and residual urine, 
and symptom scores for 
prostate assessment 
Decline of seminal 
parameters in 
middle-aged males 
is associated with 






380 men with LUTS 
42 age-matched controls (without 
LUTS) 
Clinical investigation, basic 
semen analyses, seminal IL-
6, blood samples for 
reproductive hormones and 
PSA, uroflowmetry, 
ultrasound for total prostate 
volume and residual urine, 
and symptom scores for 
prostate assessment 








122 men with increased serum 
PSA level 
255 age-matched controls (with 
serum PSA level <2.5 ng/mL) 
Clinical investigation, basic 
semen analyses, seminal IL-
6, blood samples for 
reproductive hormones and 
PSA, uroflowmetry, 
ultrasound for total prostate 
volume, ans prostate biopsy 
for histological analyses 
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4. Subjects and study design 
Initially, we investigated the reproductive parameters, and  lifestyle and edu-
cational indicators in male partners of infertile couples, attending the study 
between April 2000 and May 2010, and healthy men as the control group, 
included into study from November 2007 to October 2010.   
Subsequently, we determined associations between male reproductive 
functions and prostate-related conditions in subjects who participated in 
screening for prostate health from November 2007 to February 2011.  
The ages of all subjects in the study ranged from 45 to 69 years. 
 
 
4.1. Male partners of infertile couples and healthy volunteers 
4.1.1. Male partners of infertile couples 
The study group included 198 males attending the clinic due to infertility of 
couples with no known female risk factors (Table 2). After the first data ana-
lysis, 21 men were excluded because their semen analysis or hormonal para-
meters were missing. Furthermore, subjects with a history of couple’s infertility 
of less than 1 year (n = 5), with a prior varicocelectomy (n = 3) or with treat-
ment for hernia inguinalis (n = 5) were excluded. Finally, according to World 
Health Organization definition (WHO, 2000), 164 subjects with couple’s infer-
tility (sexually active and without contraceptive use) lasting more than 12 
months (mean ± SD 16.1 ± 2.0 months) were included in the study (Figure 5). 
Among them, 95 subjects were classified with primary infertility (no pregnancy 
at all), and 69 men with secondary infertility (unable to achieve pregnancy after 
the birth of at least one biological child)  (WHO, 2000; Nieschlag, Behre, 
2010).  
 
4.1.2. Healthy volunteers 
The control group consisted of men who considered themselves healthy and 
attended a prostate health screening at the Tartu University Hospital (Figure 5). 
In the initial phase, 364 men were in this group. Of those, 181 subjects were 
excluded according to the exclusion criteria (renal, hepatic, respiratory, endo-
crinological and/or cardiovascular diseases, or other prior chronic illnesses, 
continual use of medicine(s), prior or current problems and/or treatment for 
infertility or urogenital tumours, history of undescended testicle(s), previous 
varicocelectomy, hernio- or vasectomy, and chemo- or radiotherapy). Also, men 
that did not provide semen specimens (n = 122) were excluded. The number of 
subjects in the final group  was 61. All males in this group were identified as 
fathers through self-administered questionnaire (completed within the screening 
period). 
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4.2. Subjects of prostate health study 
In total, 639 men who underwent prostate health screening at the Tartu Uni-
versity Hospital were recruited for the study (Figure 5). Exclusion criteria for 
this study included prior or current problems and/or treatment of infertility or 
urogenital tumours, chemo- or radiation therapy in the pelvic region, previous 
varicocelectomy, hernio- or vasectomy, history of undescended testicle(s), and 
abnormal suspected findings from a digital rectal examination. None of the 
study subjects neither experienced febrile pelvic pain symptoms and acute 
urinary retention nor received therapy with antimicrobials, α1-blockers or 5α-
reductase inhibitors within 3 months before the study. 
 
 
4.2.1. Study of male genital tract inflammation 
The final study group included only the males who were willing to provide 
semen specimens (n=411). Among them, 29 subjects with reported incomplete 
semen sample or insufficient hormonal or prostate-related clinical characte-
ristics were excluded. The final study contained 382 men (mean age ± SD 55.9 
± 7.1 years). 
To detect male genital tract inflammation, seminal white blood cells (WBC) 
counts and interleukin (IL)-6, an  important marker  of male accessory gland 
inflammatory process (Jungwirth et al., 2013) and the leading cytokine mea-
sured in seminal tract inflammation since 1990s (Comhaire et al., 1994), were 
determined. 
Subjects were divided into three groups, based on their seminal WBC count. 
Two of them were separated according to cut-off level defined by receiver 
operating characteristics curve (ROCC) analysis (males with mild and moderate 
white blood cells count, i.e. WBC <0.35 x 106/mL and 0.35–0.99 x 106/mL), 
presented in Paper II. The third group included subjects with leukocytospermic 
values that exceeded the WHO (2011) threshold for WBC count in semen (≥ 1 x 
106/mL). 
Additionally, subjects were separated into two groups according to their 
seminal IL-6 levels. The cut-off level of IL-6 was calculated by ROCC analysis 
(IL-6 <57.0 ng/L and ≥57.0 ng/L), published in Paper II. 
 
 
4.2.2. Study of male lower urinary tract symptoms and  
prostate enlargement  
The final study group included males who were willing to provide semen 
specimens during initial (n=411) and repeated visits (n=37). Among them, 29 
subjects with reported incomplete sample or insufficient hormonal or prostate-
related clinical characteristics during their initial appointment were excluded, 
but three of them qualified after a secondary consultation and semen analysis. 
The final study contained 422 men (mean age ± SD 56.1 ± 6.7 years).  
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According to the International Prostate Symptom Score (I-PSS) question-
naire, 380 patients presented with LUTS (mean age 56.3 ± 7.2 years) and the 
remaining 42 subjects were without LUTS (mean age 55.8 ± 6.9 years). For 
further analyses, men were grouped according to I-PSS and total prostate 
volume (TPV). 
Subjects were divided into four groups based to their I-PSS: men without 
LUTS (I-PSS 0) and with mild (I-PSS 1–7), moderate (I-PSS 8–19), and severe 
(I-PSS 20–35) symptoms (Oelke et al., 2013). Separation of subjects according 
to TPV was made using the cut-off levels (<30 and ≥30 mL), described in pre-
vious large-scale and long-term medical studies (Roehrborn et al., 2004; 




4.2.3. Study of histologically confirmed prostate conditions and  
prostate-specific antigen 
The final study group included subjects who were willing to provide semen 
specimens (n=411). Among them, 29 subjects with a reported incomplete semen 
sample or insufficient hormonal or prostate-related clinical characteristics, and 
5 males with diagnosis of prostate cancer with extracapsular extension (primary 
tumour stage ≥T3, Heidenreich et al., 2013) were excluded. The final study 
contained 377 men (mean age ± SD 55.9 ± 7.0 years).  
To compare male seminal parameters with different serum PSA levels, 
subjects were divided into three groups according to risk for prostate patho-
logies (serum PSA level <1.0 ng/ml, 1.0–2.49 ng/mL, and ≥2.5 ng/mL) in 
middle-aged males (Loeb et al., 2006; Vickers et al., 2010; Lilja et al., 2011; 
Heidenreich et al., 2013). Among the subjects, 122 males presented with 
elevated serum PSA levels (Loeb et al., 2006; Heidenreich et al., 2013) and 
were separated into three subgroups according to prostate histological finding. 
The remaining 255 subjects with serum PSA level less than 2.5 ng/mL were 
















Figure 5. Subjects formation for the study of reproductive function in male partners of 
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5.1. Clinical examination 
Physical examination included calculated body mass index (BMI) and genital 
pathologies (i.e. penis, testicles, groin and prostate, by digital rectal exami-
nation). BMI was calculated as weight in kilograms divided by height in meters 
squared. Mean testicular size was calculated as the mean volume of the right 
and left testicles, as measured with an orchidometer made of birch wood 




Participants in the study completed questionnaires that included information 
about education, previous and current diseases, and lifestyle factors. In the 
prostate health study (chapter 4.2.), subjects completed symptom scores for 
prostate assessments, including the Estonian version of the National Institutes of 
Health Chronic Prostatitis Symptom Index (NIH-CPSI) score containing 
questions about chronic pelvic pain or discomfort, urination and bothersome 
symptoms (Korrovits et al., 2006), and the I-PSS (Oelke et al., 2013) for 
irritating, obstructive and, nocturnal LUTS.  
 
 
5.3. Semen analyses 
5.3.1. Basic semen parameters 
Semen was obtained by masturbation and ejaculated into a sterile collection 
tube in a private room near the laboratory. Ejaculated semen was incubated at 
37°C for 30 to 40 minutes for liquefaction.  
All subjects were studied by the same criteria (WHO, 1999, 2011) at the 
Tartu University Hospital. Participants of the study were examined by one 
technician who had undergone extensive special training on laboratory standar-
dization of semen sample analysis. 
Routine semen analyses, performed according to WHO guidelines (WHO, 
1999, 2011), included semen volume, total sperm count, concentration, motility, 
morphology, and WBC count. The recommended abstinence period before the 
ejaculation was a minimum of 48 hours but not longer than 7 days. The actual 
period of abstinence was calculated in full days between the current and 
previous ejaculation, as reported by the subjects.  
Semen volume was determined by weighing the collection tube with the 
semen sample and subsequently subtracting the predetermined weight of the 
empty tube, assuming 1 g = 1 mL of semen. Motility assessment was performed 
in duplicate, and the average value of the two samples was calculated. Sperm 
concentration was assessed by the improved Neubauer haemocytometer. 
Morphology smears were stained with Papanicolaou method and spermatozoa 
were evaluated according to strict criteria (Menkveld et al., 1990). 
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5.3.2. Cytological analyses for detection of white blood cells  
Semen smears for detecting WBCs were air-dried, stained with Bryan-Leish-
man method and examined by oil-immersion microscopy. 
Seminal WBC concentration was calculated from known sperm con-
centration (as 106/mL), according to the following formula:  
 
(number of WBC counted/number of sperm counted) x semen sperm concentration 
 
 
5.3.3. Detection of seminal interleukin-6 
IL-6 levels in seminal plasma (100 µl of specimen was required for the assay) 
were measured with the Immulite automated chemiluminescence immunoassay 
IMMULITE 2000 analyzer (Kit Catalog Number L2K6P2, Immulite Siemens 
Healthcare Diagnostics Inc., Deerfield, IL, USA) according to the manu-
facturer’s instructions. Solid-phase, enzyme-labeled sequential chemilumi-
nescent immunometric assays were performed automatically on the IMMU-
LITE 2000 analyzer, with two incubation cycles per 30 minutes, an analytic 
sensitivity of 2 pg/ml, and a calibration range of up to 1000 pg/ml. Granules 
coated with antibodies to IL-6 were mixed with the samples. Antibodies were 
highly specific to IL-6 and had no cross-reactivity with other interleukins, 
TNFα, or IFN-γ (Immulite 2000 IL-6). Intra- and inter-assay coefficients of 
variation were 4.7 and 5.3%, respectively. 
 
5.4. Blood analyses 
Venous blood was obtained from the cubital vein between 8 a.m. and 11 a.m. 
after an overnight fasting or light morning meal. Samples were centrifuged, 
serum was isolated, and specific markers were detected within 2 hours of 
collection at the United Laboratories of Tartu University Hospital.  
 
 
5.4.1. Reproductive hormones 
The levels of FSH (Kit Catalog Number L2KFS1), LH (Kit Catalog Number 
LKLH1), testosterone (Kit Catalog Number LKTW1), E2 (Kit Catalog Number 
LKE21) and SHBG (Kit Catalog Number LKSH1) were measured in blood 
plasma with the Immulite Automated Chemiluminescence Immunoassay 
IMMULITE analyzer (Immulite Siemens Healthcare Diagnostics Inc., Deer-
field, IL, USA), according to the manufacturer’s instructions.  
Solid-phase, enzyme-labeled sequential chemiluminescent immunometric 
assays were  performed automatically on the IMMULITE  analyzer with one 
incubation cycle per 30 minutes for FSH, LH, and SHBG, and one incubation 
cycle per 60 minutes for testosterone and E2. Calibration ranges were 0.1–170 
IU/L for FSH, 0.1–200 IU/L for LH, 0.7–55.0 nmol/L for testosterone, 73.0–
7,342 pmol/L for E2, and 0.2–180 nmol/L for SHBG.  
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Intra- and inter-assay coefficients of variation were 4.2 and 8.0% for FSH, 
4.0 and 7.1% for LH, 6.3 and 9.4% for testosterone, 7.5 and 13% for E2, and 3.4 
and 4.1% for SHBG (Immulite 2000 FSH, 2005; Immulite/Immulite 1000 LH, 
2006; Immulite/Immulite 1000 Total Testosterone,  2006; Immulite/Immulite 
1000 Estradiol, 2006; Immulite/Immulite 1000 SHBG, 2005). 
 
 
5.4.2. Prostate-specific antigen 
PSA levels (Kit Catalog Number L2KUP6) in blood plasma were measured 
with the Immulite Automated Chemiluminescence Immunoassay IMMULITE 
analyzer (Immulite Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA), 
according to the manufacturer’s instructions. Solid-phase, enzyme-labeled 
sequential chemiluminescent immunometric assays were performed auto-
matically on the IMMULITE analyzer with two incubation cycles per 30 mi-
nutes. The calibration range was 0.003–20 ng/mL. Intra- and inter-assay co-
efficients for variation of PSA were 0.8 and 2.7%, respectively (Immulite 2000 
Third Generation PSA, 2006). 
 
5.5. Ultrasonography and uroflowmetry 
All men in the prostate health study (chapter 4.2.) measured for main prostate 
parameters (Oelke et al., 2013), including TPV and postvoided residual urine 
(PVR) by trans-rectal or abdominal ultrasound (using Logiq 5 Pro by General 
Electric, Milwaukee, WI, United States) and urinary flow rates by uroflowmetry 
(using Urodyn 1000 by Medtronic, Minneapolis, MIN, United States). 
 
5.6. Histological analyses  
In the prostate health study, subjects with serum PSA levels of at least 2.5 
ng/mL (Loeb et al., 2006; Heidenreich et al., 2013) were recruited for prostate 
12-core transrectal ultrasound-guided biopsies within 1 month after the initial 
analyses. Biopsies were taken from right and left lobe of the prostate using 
standard-score schemes (Figure 6) and18-gauge biopsy needles (Pro-Mag by 
Medical Device Technologies Inc., Gainesville, FL, USA). The samples were 
examined at the Tartu University Hospital by the experienced pathologist(s). 
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Figure 6. Algorithm of transrectal ultrasound-guided 12-core prostate biopsy. 
 
5.7. Statistical analyses 
For statistical analyses, SigmaStat (Systat Software, Chicago, IL, USA), Excel 
(Microsoft, Redmond, WA, USA) and R (R Foundation for Statistical Com-
puting, Vienna, Austria)  software programs were used. 
Differences between groups were determined by the Mann-Whitney or 
Kruskal-Wallis tests. Group or groups that differed were isolated by multiple 
comparison procedures (Dunn’s method). Spearman product moment corre-
lation was used to determine correlations between age and reproductive or 
prostate-related parameters. According to WHO reference ranges for semen 
volume, sperm concentration, and sperm total motility (WHO, 2011), areas 
under ROCCs and diagnostic test characteristics (95% confidence intervals, CI) 
for seminal inflammatory markers were designed using R software to estimate 
semen pathology.  
A multiple regression model was constructed to uncover significant effects 
of education, lifestyle factors, infertility/non-infertility status and age on repro-
ductive parameters; and secondly, the relations between LUTS, male genital 
tract inflammatory markers and semen parameters were detected. 
Education, lifestyle and environmental factors in male partners of infertile 
couples and healthy volunteers, using the Chi-Square or Fisher’s exact test, 
were compared.  
Statistical significance was assumed at p < 0.05 for all parameters. 
 
5.8. Ethical considerations 
Participation in the study was voluntary. Informed consent was obtained from 
all study subjects. The study was approved by the Ethics Review Committee on 
Human Research of the University of Tartu (certificate 166/T-14, 17.12.2007, 
No. 174/T-16, 22.09.2008 and 191/M-16, 29.03.2010). 
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RESULTS AND DISCUSSION 
6. Reproductive function in middle-aged male:  
association with lifestyle and couple’s infertility 
6.1. Semen parameters and related indicators in healthy men and 
male partners of infertile couples (Paper I) 
In our study, serum E2 levels, total sperm count and sperm concentration, pro-
portion of morphologically normal sperms in semen, and testicular volume were 
significantly lower in male partners of infertile couples (n=164) compared to 
healthy men (n=61), the results are summarized in Table 3. Moreover, we found 
that subset of men with three normal variables (semen volume ≥1.5 mL, sperm 
concentration ≥15 x 106/mL, and total motility ≥40%; WHO, 2011) was signi-
ficantly lower among men in infertile couples compared to healthy subjects 
(41.2% versus 68.3%, P < 0.001). At the same time no significant differences in 
semen quality and related parameters between subjects with primary and 
secondary infertility were detected. To our knowledge, similar findings in males  
over 45 years have not been published previously. 
Testicular size was in positive correlation with the main sperm characte-
ristics in subjects of both groups. Although reduction of testicular volume is 
usually observed only after the seventh decade of life, some prior studies have 
described significantly lower testicular volume in chronically ill men compared 
to healthy subjects in a similar age group (Handelsman, Staraj, 1985). To our 
knowledge, there are no prior comparative data describing correlations between 
testicular size and semen parameters of men aged over 45 years.  
Besides testicular volume, sperm concentration and morphology could be 
also good predictors of testicular function. Although previous studies (Ng et al., 
2004; Auger et al., 1995) have demonstrated that decreased sperm count and a 
lower proportion of normal sperms are related to male aging, we did not find 
any significant influence of male age on semen quality and testicle volume in 
our study. Instead, we found differences in sperm parameters between healthy 
males and male partners of infertile couples. Therefore, it may be assumed that 
impaired sperm quality is not related to age in general, but to more specific 
physiological causes and lifestyle-related risk factors. 
We also found that main sperm parameters were in negative correlation with 
serum FSH and LH levels in both groups. Correlation coefficients for male age, 
reproductive hormones, mean testicular size, and semen characteristics for both 
groups are presented in Table 2 of Paper I.  
 
6.2. Impacts of general health, lifestyle, and educational factors on 
reproductive function (Paper I) 
According to the data obtained from self-completed questionnaires on lifestyle 
risk factors, education, and general health, we determined that physical activity 
and sexual capability were higher in healthy men, whereas coital frequency and 
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history of sexually transmitted diseases were higher in men of infertile couples 
(Table 3 in Paper I); education, smoking and alcohol use were similar in both 
groups. Previous results from studies of older males are limited (Eskenazi et al., 
2003; Hellstrom et al., 2006), and data from younger subjects are controversial. 
For example, the study of infertile couples from Künzle et al. (2003) showed 
that smokers had about 20% lower sperm concentration and total sperm count 
compared to non-smokers, whereas current smoking status had no independent 
effects on semen quality in young European males (Jensen et al., 2004). There-
fore, additional further and detailed investigations in this topic are needed. 
We also found that sexual capability was in significant positive correlation 
with total sperm count (r=0.368, p=<0.001), sperm concentration (r=0.386,  
p= <0.001) and sperm motility (r=0.194, p=0.020), whereas physical activity 
was positively correlated with sperm concentration (r=0.267, p=0.001) and 
negatively correlated with semen volume (r=-0.229, p=0.006). 
Multiple regression analysis was performed subsequently to uncover signi-
ficant effects of education, lifestyle factors, status of infertility/non-infertility 
and age on reproductive parameters. Analysis confirmed positive associations 
of total sperm count and sperm concentration with sexual capability (p=0.001 
and p=0.006, respectively), and  a negative association between physical acti-
vity and semen volume (p=0.033). Also, intercourse frequency was negatively 
correlated with total sperm count and sperm concentration (p=0.024 and 
p=0.033, respectively). According to these findings, we assume that semen 
quality in men over 45 years may be related to certain lifestyle risk factors and 
needs additional detailed investigations. 
 
7. Reproductive function in middle-aged males: 
association with prostate-related conditions  
7.1. Role of genital tract inflammation (Paper II) 
Subjects were grouped according to seminal WBC count and IL-6 levels (chapter 
4.2.1.), these two markers were in positive correlation (r=0.185, p<0.001).    
Semen volume, total sperm count and sperm motility were lower in patients 
with genital tract inflammation (Tables 5 and 6 in Paper II). Both seminal 
inflammatory markers (WBC count and IL-6 level) were in negative correlation 
with semen volume and total sperm count for all subjects. Moreover, WBC 
count was negatively correlated with sperm motility (Table 2 in Paper II).  
Seminal IL-6 levels showed positive correlations with age and TPV, and 
both seminal inflammatory markers were positively correlated with serum PSA 
level (Table 2 in Paper II),. Although results of prior studies are controversial 
(Hochreiter, 2008; Loeb et al., 2009), similar associations between semen 
parameters and seminal inflammatory markers were demonstrated in studies of 
younger, asymptomatic subjects (Korrovits et al., 2008), and between serum 
PSA levels and seminal inflammatory markers in expressed prostatic secretion  
of aging males (Ausmees et al., 2009a). Statistically significant correlations 
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between semen volume, sperm parameters and seminal inflammatory markers 
are presented in Figure 7. 
Additionally, we determined seminal WBC counts and IL-6 levels in sub-
jects with normal and declined semen parameters, defined by WHO reference 
ranges (2011). IL-6 levels in semen of men with three normal semen variables 
(semen volume ≥1.5 mL, sperm concentration  ≥15 x 106/mL, and total motility 
≥40%) were significantly lower compared to subjects with at least one abnormal 
sperm parameter (mean ± SD 49.8 ng/mL ± 38.4 versus 90.4 ± 150.3 ng/mL, 
respectively, p=0.001). The seminal WBC counts were similar for both groups. 
One of the striking findings in our study were higher serum E2 levels and 
estradiol-to- testosterone ratios in patients with elevated seminal inflammatory 
markers (Tables 5 and 6 in Paper II). To our knowledge, no prior studies report 
hormonal levels in subjects with genital inflammation. However, there is 
evidence from animal models that prostatitis may change the balance of sexual 
hormones (Stoker et al., 1999; Cutolo et al., 2004).  
 
 
7.2. Roles of lower urinary tract function and  
prostate enlargement (Paper III) 
Subjects were grouped according to I-PSS and TPV (chapter 4.2.2.). We found 
that total sperm count and sperm concentration decreased as I-PSS and TPV 
increased; moreover, semen volume decreased in case of elevated I-PSS (Tables 
1–1 and 1–2 in Paper III). The same tendencies were revealed with correlation 
analyses, where lower urinary tract symptom scores (I-PSS and NIH-CPSI) and 
TPV were negatively associated with semen parameters (Table 2 in Paper III). 
Also, maximum urinary flow rate (QMAX) was in positive correlation with 
semen volume and in negative correlation with time of abstinence before sperm 
analyses. Statistically significant correlations between semen parameters and 
prostate-related assessments are presented in Figure 7.  
Additionally, we determined I-PSS and TPV in subjects with normal and 
declined semen parameters, defined by WHO reference ranges (2011). Total 
prostate volumes for men with three normal semen variables (semen volume 
≥1.5 mL, sperm concentration ≥15 x 106/mL, and total motility ≥40%) were 
significantly lower compared to subjects with at least one abnormal sperm 
parameter (mean ± SD 29.2 ± 10.3 versus 38.4 ± 14.1 mL, respectively, 
p=0.026). Similar differences were found for total I-PSS (mean ± SD 9.3 ± 5.8 
versus 14.4 ± 7.3 score-points for subjects with normal and at least one ab-
normal sperm parameter, respectively, p=0.003).  
Although urinary dysfunction is a classic clinical symptom related to 
prostate pathologies (Oelke et al., 2013), and associations between prostate and 
reproductive functions are presumable, the connections between LUTS and 
reproductive quality in middle-aged men have not yet been described.   
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7.3. Impacts of premalignant and  
malignant prostate conditions (Paper IV) 
Subjects were grouped according to serum PSA levels and prostate histological 
findings (chapter 4.2.3.). We found significantly decreased sperm concent-
rations and total sperm counts in males with premalignant and malignant 
prostate conditions, compared to subjects without (pre)malignancies and age-
matched controls. In addition, seminal IL-6 levels were increased in subjects 
with biopsy-confirmed BPH and/or chronic prostatitis, compared to age-
matched controls (Table 2 in Paper IV).  
Several controversial epidemiological studies about the relationships between 
male infertility and prostate cancer exist in the literature (Harlap et al., 2007; 
Jorgensen et al., 2008; Walsh et al., 2010; Ruhayel et al., 2010). Although the 
topic is relevant, there is only one clinical study that included 26 older men with 
histological diagnosis of organ-confined prostate cancer. The prostate cancer 
group had similar seminal parameters as the 27 subjects in age-matched control 
group with no evidence of prostate cancer (Ng et al., 2004). However, our study 
found that semen quality and related reproductive indicators were impaired in 
subjects with premalignant and malignant prostate conditions, compared to men 
without (pre)malignancies and age-matched controls. These alterations may be 
due to changes in general health status, malnutrition and gonadal function (Dohle, 
2010), but may also be due  to (partial) obstruction of prostate and accessory 
glands. Therefore that topic warrants more detailed investigations.  
An unexpected finding of our study was the elevated serum FSH level in 
subjects with premalignant and malignant prostate conditions (Table 2 in Paper 
IV). Although the connection between serum FSH and spermatogenesis is well-
accepted (Jarow et al., 2011; Jungwirth et al., 2013), little is known about the 
relationships between serum FSH and prostate. Besides direct connections have 
not been reported, initial findings indicate that FSH may be expressed by prostatic 
cells and upregulate aromatase activity in prostate (Dirnhofer et al., 1998). 
 
 
7.4. Associations between reproductive function and  
prostate-specific antigen (Paper IV)  
We investigated serum PSA levels in 377 subjects. Increased serum PSA levels 
were negatively correlated with semen volume, total sperm count, and sperm 
concentration. PSA levels were also associated with TPV, urinary flow rate and 
seminal IL-6 levels (Table 1 in Paper IV).  
Also, we compared serum PSA level in subjects with normal and declined 
semen parameters, defined by WHO reference ranges (2011). PSA levels in men 
with three normal semen variables (semen volume ≥1.5 mL, sperm density ≥15 x 
106/mL, and total motility ≥40%) were significantly lower compared to subjects 
with at least one lowered sperm parameter (mean ± SD 1.5 ± 1.4 versus 2.5 ± 2.5 
ng/mL, respectively, p=0.002). Statistically significant correlations of semen 





We have not found prior reports associating serum PSA and seminal function in 
middle-aged males. Whereas similar data on younger subjects are also limited 
(Lackner et al., 2006), this topic needs a more detailed investigation. 
 
7.5. Multiple regression analysis of seminal and  
prostate-related parameters  
Multiple regression analysis was performed in subjects who participated in the 
study of male genital tract inflammation, to uncover the significant effects of 
selected prostate-related parameters and seminal inflammatory markers on 
semen quality. Analysis indicated that sperm concentration, total sperm count 
and the proportion of normal spermatozoa were most of all influenced by 
prostate enlargement and total I-PSS, whereas sperm motility was associated 
with the total NIH-CPSI score and semen WBC count. The results are sum-
marized in Table 4, indicating similar tendencies as revealed in above-described 
univariate analyses and in Tables 7 and 8 of Paper II, and Table 4 of Paper III.  
Figure 7. Statistically significant correlations  between sperm parameters, seminal in-
flammatory markers and prostate-related assessments.  
 
1 Spearman rank-correlation coefficient 
 sperm parameters (SEVOL, semen volume, TSC, total sperm count, CONC, sperm concentration, 
MOTIL, sperm motility) 
 seminal inflammatory markers (WBC, white blood cells, IL-6, interleukin-6) 
 prostate-related assessments (PSA, prostate-specific antigen, I-PSS, International Prostate Symptom 
Score, NIH-CPSI, National Institute of Health Chronic Prostatitis Symptom Index, QMAX, maximum 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The main aim of our study was to define reproductive function and to identify 
possible influences of prostate conditions on male reproduction in middle-aged 
males. Initially, we compared reproductive function and educational, lifestyle-
related and environmental factors of healthy subjects and male partners of 
infertile couples. Thereafter we examined the associations between reproductive 
function and different prostate conditions in middle-aged subjects who under-
went the screening for prostate health. 
The main finding in our study was that reproductive function in middle-aged 
subjects is not only related with general aging as described previously (Sar-
torius, Nieschlag, 2010; Stewart, Kim, 2011). The study indicated that semen 
parameters and associated reproductive indicators are associated significantly 
with certain lifestyle factors, including prior history of sexually transmitted 
diseases. In addition, fertile men had higher sexual capability and physical 
activity levels. This study also revealed significant differences in sperm quality 
and associated reproductive indicators, such as testicular size, between healthy 
men and male partners of infertile couples. Although reduction of testicular 
volume is generally observed only after the seventh decade of life, prior studies 
have described significantly lower testicular volume in chronically ill men 
compared to healthy subjects in similar age group (Handelsman, Staraj, 1985). 
In our study, similar tendencies were revealed when we compared males of 
infertile couples to healthy subjects. Moreover, the volume of testicles was 
positively correlated with the main sperm characteristics in both groups. To our 
knowledge, there are no prior analyses describing correlations between testi-
cular size and semen parameters of men over 45 years old. Indeed, similar data 
on younger males are also limited. 
Our study showed that serum E2 levels were significantly higher in healthy 
men compared to males of infertile couples. To our best knowledge, similar 
findings for middle-aged males have not been published previously. However, it 
is known that estrogens may act via negative feedback on serum FSH and LH 
(Nicol et al., 2002; Pitteloud et al., 2008). Therefore, it is not surprising that one 
previous in vitro study has identified E2 as a germ cell survival factor (Penti-
kainen et al., 2000). We also found altered serum E2 levels in subjects with 
elevated seminal inflammatory markers in the study of prostate-related diseases 
and male reproductive function. While there are no available reports that 
specifically focus on hormone levels in male subjects with genital tract inflam-
mation, evidence from animal models indicates that prostatitis may change the 
balance of sexual hormones. For example, Stoker et al. (1999) demonstrated the 
roles of perinatal oestrogenic exposure on prostate volume and increased 
prostatitis rates in rats. Otherwise, decreased testosterone level may also affect 
experimental prostatitis and suppress immune function in rat models (Cutolo et 
al., 2004). Also, our study of male genital tract inflammation and male repro-
ductive function showed that increased seminal inflammatory marker (WBC 
count and IL-6) levels were associated with reduced semen parameters. 
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Although prostatitis and male genital accessory gland inflammation are not 
well-accepted causes of male infertility (Jungwirth et al., 2013), there is strong 
evidence that male genital tract inflammation may affect reproductive function, 
including semen parameters (Shindel, Naughton, 2004; Engeler et al., 2006), 
through (partial) occlusion of the seminal tract (Dohle, 2003). 
According to our findings, reduced seminal parameters are also associated 
with prostate enlargement and LUTS in middle-aged males. These alterations 
may be related to changes in general health status, malnutrition and gonadal 
function (Dohle, 2010), but may also be due to subsequent (partial) obstruction 
of male accessory glands and/or prostate damage. Although the prostate, an 
accessory gland of the male reproductive system, is directly related to male 
reproductive, sexual, and ejaculatory functions (McVary, 2006; Hellstrom et al., 
2009), there are only few clinical studies relating prostate-related conditions to 
reproductive function or sperm quality in middle-aged men (Rolf et al., 2002; 
Ng et al., 2004; Ruhayel et al., 2010; Walsh et al., 2010).  
In the literature and in clinical practice, relations between prostate patho-
logies and serum PSA levels are well-established (Sciarra et al., 2008; Oelke et 
al., 2013). Because we have initial results related with TPV, serum PSA level 
and seminal parameters (Ausmees et al., 2009b), we may assume that there 
should be connections between serum PSA levels and male reproductive 
parameters. In the present study, serum PSA levels correlated negatively with 
semen parameters, including semen volume, sperm motility, and total sperm 
count, and positively with seminal inflammatory markers, including IL-6 levels 
and WBC counts. Moreover, semen quality and related reproductive indicators 
were impaired in subjects with premalignant and malignant prostate conditions, 
compared to age-matched controls and subjects without (pre)malignancies. 
Therefore, according to these data, increased serum PSA levels in middle-aged 
males indicate not only prostate-related conditions, but may also desribe risks 
for impaired reproductive quality.  
An unexpected finding of our study were elevated serum FSH levels in 
subjects with premalignant and malignant prostate conditions. Although there 
are reported connections between serum FSH and spermatogenesis (Jarow et 
al., 2011; Jungwirth et al., 2013), little is known about relations between serum 
FSH and prostate. To our knowledge, direct connections have not been 
reported. However, preliminary findings indicate that FSH may be expressed by 
prostatic cells to upregulate aromatase activity (Dirnhofer et al., 1998). 
Interestingly, similar elevated serum FSH levels have been reported in 
subjects with carcinoma in situ of the testicles (Elzinga-Tinke et al., 2012). 
Despite analogous findings, we assume that elevated serum FSH is not (only) 
due to (pre)malignancy, but that complex aging process may affect via HPT 
axis, combining endocrine, cellular and structural alterations in male repro-
ductive organs, including prostate and testicles. 
The present study has some limitations. First, similar to most prior semen 
quality reports, our study included only men who attended a screening in 
outpatient clinic and were willing to provide semen specimens. Therefore, 
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included subjects may not accurately represent the general population of males 
over 45 years old. Secondly, because subjects of that age mostly do not wish to 
perform additional analyses, and participation in our study was voluntary, 
assessments of seminal parameters were performed on single semen sample (per 
appointment). Similar methods have been described in prior studies of men over 
40 years old (Rolf et al., 2002; Ng et al., 2004).  
Our study also has several strengths. Almost three-quarters of previous 
studies on reproductive function in middle-aged men did not consider the 
duration of abstinence before semen analyses (Sartorius, Nieschlag, 2010; 
Stewart, Kim, 2011). In our study, the recommended abstinence period (WHO, 
1999, 2011) was 48 hours to 7 days for all participants. During the study, 
subjects were studied by the same criteria (WHO, 1999, 2011), in the same 
centre and laboratories. Also, age-matched controls were included in accor-
dance with defined requirements (Engeler et al., 2006). 
For further research, more detailed and prolonged studies are required to 
understand the causes of altered reproductive function in aging male, to 
promote ongoing healthy lifestyle, and to prevent life-long risk factors that may 




















Our study updated the current knowledge of reproductive function in middle-
aged males and uncovered  the role of prostate conditions in male reproduction. 
Some of these findings have not been described previously. 
1) There are obvious differences in testicular volume, main sperm parameters 
and serum hormonal levels between men of infertile couples and healthy 
middle-aged males. Serum E2 levels, total sperm count and sperm con-
centration, proportion of morphologically normal sperms in semen, and 
testicular volume are lower in male partners of infertile couples. These data 
revealed that sperm quality and associated reproductive parameters are not 
only related to general male aging as described previously. 
2) Semen parameters in middle-aged males are associated with lifestyle-related 
influences, including physical activity and history of sexually transmitted 
diseases. Reproductive function of aging males may be improved by mini-
mizing the life-long negative role of these risk factors. 
3) Increased male genital tract inflammatory markers are associated with 
reduced semen parameters and increased serum PSA and E2 levels. Similar 
results have been reported in younger men with asymptomatic prostatitis, 
indicating that decreased seminal function and elevated serum PSA may be 
due to prostate (partial) damage at younger age with long-term accumu-
lation of inflammation-related influences thereafter. 
4) Deterioration of seminal parameters in middle-aged men is associated with 
prostate enlargement and LUTS. Therefore, prostate volume is important 
not only for male urinary function and bothersome symptoms, but may also 
have important role in male fertility. Although assessments of prostate and 
LUTS may not replace semen analysis for evaluating male reproductive 
status, there is need for more detailed investigations to uncover the path-
ways behind these associations as well as possible related conditions.  
5) Premalignant and malignant prostate conditions impair semen quality and 
related reproductive indicators. These alterations may be related to changes 
in general health status, malnutrition and gonadal function as described 
previously, but may also be associated with (partial) obstruction of prostate 
and accessory glands.  
6) Elevated serum PSA levels are associated with decreased semen quality in 
middle-aged subjects. These findings, aAlthough results of prior epidemio-
logical studies of male infertility and prostate cancer are controversial, these 
findings may suggest that infertile or subfertile young males should attend 
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SUMMARY IN ESTONIAN 
Keskealiste meeste reproduktiivfunktsioon:  
seos eesnäärme, elustiili faktorite ja paari viljatusega 
Mehe reproduktiivtervise uuringutele pööratakse kogu maailmas järjest rohkem 
tähelepanu järgnevatel põhjustel:  
1) Sündivate laste vanemate keskmise vanus kasvab arenenud riikides erine-
vatel sotsiaal-majanduslikel põhjustel. Eelkõige mõjutavad seda hariduslikud 
ja tööalase karjääriga seotud otsused ning uue partnersuhtega seonduvad 
ootused lisanduvatele järeltulijatele;   
2) Kehavälise viljastamise meetodite odavnemine ja kättesaadavuse parane-
mine. Eelkõige mõjutab see vanemas eas ning eelnevalt lastetute paaride 
reproduktiivsusega seotud otsuseid. Ligi 15% reproduktiivses eas paaridest 
on probleeme loomulikul teel rasestumisega, rohkem kui 1/4 neist juhtudest 
on seotud mehepoolsete põhjustega (Jungwirth et al., 2013).  
Need muutused ning lisaks elanikkonna keskmise oodatava eluea tõusuga seon-
duvad meditsiinilised aspektid annavad meeste reproduktiivtervislikule käitu-
misele ja valdkonnaga seotud arengutele ka olulise sotsiaalse ning majandusliku 
sisu.  
Kuidas vanus ja vananemine täpselt mehe reproduktiivfunktsiooni mõjuta-
vad, on siiani vaieldav, sest puuduvad vastavad prospektiivsed uuringud. Vara-
semate kliiniliste uuringute alusel (Kidd et al., 2001; Kuhnert, Nieschlag, 2004; 
Sartorius, Nieschlag, 2010; Harris et al., 2011) võib öelda, et vanus on seotud 
seemnevedeliku mahu, spermide liikuvuse ja normaalsete seemnerakkude hulga 
langusega, kuid spermide kontsentratsiooni vanus oluliselt ei mõjuta (Kidd et 
al., 2001). Arvatakse, et vanusest sõltuvatel mehe viljakusnäitajate muutustel 
võib lisaks ealisele mõjule olla mitmeid lisanduvaid põhjusi –  eelnevad trau-
mad ja vigastused,  vaskulaarsed, hormonaalsed ja metaboolsed haigused, orga-
nismi anatoomilised ja füsioloogilised muutused ning elustiili- ja keskkonna-
faktorid. 
Vanus on ka üks olulisemaid eesnäärmemahu suurenemise ja urineerimis-
häirete tekkega seotud riskifaktoreid. Ligi 50% viiekümne-aastastest meestest 
kurdab urineerimisega seotud kaebuste üle, alates viiekümnendatest eluaastatest 
tõuseb urineerimiskaebustega meeste osakaal ca 10% ühe eludekaadi kohta 
(Oelke et al., 2013). Teadaolevalt puuduvad hetkel uuringud eesnäärmemahu 
suurenemise, alumiste kuseteede kaebuste ning meeste reproduktiivfunktsiooni 
seoste kohta. 
Eelnevad uuringud on viidanud, et mehe sugutrakti krooniline põletik mõ-
jutab lisaks seemnerakkude kvaliteedi langusele ka paari viljakust ja kehavälise 
viljastamise protseduuride tulemusi. Siiski on tulemused esialgsed ja vastu-
olulised ning vajavad põhjalikumaid uuringuid (Jungwirth et al., 2013). Hetkel 
on meil andmed ainult ühe retrospektiivse uuringu kohta, mis kirjeldab sugu-
traktipõletiku rolli vanemate meeste viljakusnäitajate riskifaktorina. Rolfi 
(2002) poolt Münsteris viljatusprobleemidega meeste seas läbi viidud uuring 
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näitas, et sugutrakti põletike esinemissagedus alla 25-aastaste meeste seas oli 
6% ja üle 40-aastaste meeste hulgas ligi 14%. Lisaks leiti nimetatud uuringus, et 
sugutrakti põletikuga meestel oli madalam spermide koguarv ja seemnevedeliku 
maht võrreldes meestega, kelle suguteedes põletikku ei leitud. Kuna võrreldud 
gruppides oli sarnane munandimaht, võib uuringu autorite arvates olla üheks 
vanemate meeste reproduktiivfunktsiooni languse põhjuseks kroonilisest põle-
tikust tingitud suguteede (osaline) sulgus (Rolf et al., 2002). 
Eesnäärmevähi ja mehe reproduktiivfunktsiooni võimalike seoste kohta on 
siiani avaldatud vaid üks uuring. Selles uuriti 52–79-aastaseid mehi, kellel oli 
eelneval histoloogilisel uuringul diagnoositud eesnäärmekasvaja (Ng et al., 
2004). Uuringus osalenud meeste viljakusnäitajad olid sarnased samas vanuses 
kontrollgrupi meeste viljakusnäitajatega. Samas on varasematest uuringutest 
teada, et kuse-sugutrakti kasvajalised muutused (nt munandivähk) mõjutavad 
oluliselt mehe reproduktiivsust ja järglaste arvu (Jungwirth et al., 2013) juba 
enne kasvaja diagnoosimist, mistõttu vajab eesnäärmevähi ja mehe reproduk-
tiivfunktsiooni võimalike seoste ning ühiste riskifaktorite täpsustamine täien-
davaid uuringuid. Teadmised keskealiste ja vanemate meeste reproduktiiv-
funktsioonist ning seda mõjutavatest faktoritest on kasinad, mis tingis vajaduse 




Uurimistöö eesmärgiks oli täpsustada keskealiste meeste reproduktiivfunktsioo-
ni ning hinnata selle võimalikku seost erinevate eesnäärmehaiguste ja elustiili-
faktoritega.  
Uurimistöö täpsemad ülesanded olid: 
1) Võrrelda keskealiste tervete meeste ja viljatute paaride meespartnerite 
viljakusnäitajaid; 
2) Kirjeldada elustiili ja haridustaseme mõju keskealiste meeste viljakus-
näitajatele; 
3)  Hinnata sugutraktipõletiku mõju keskealiste meeste viljakusnäitajatele; 
4)  Selgitada alumise kusetrakti sümptomaatika, eesnäärmemahu ning seotud 
mõjurite osa keskealiste meeste viljakusnäitajatele; 
5)  Määrata premaliigsete ja pahaloomuliste eesnäärmehaiguste mõju kesk-
ealiste meeste viljakusnäitajatele; 
6) Täpsustada eesnäärme-spetsiifilise antigeeni võimalikku seost keskealiste 
meeste viljakusnäitajatega.   
 
 
Uuritav materjal ja meetodid 
Viljatute paaride meespartneritena kaasati uuringusse 198 meest (vanus 45–
60 eluaastat), kes osalesid kliinilises uuringus “Mehepoolse viljatuse põhjused”. 
Uuringusse kaasamise kriteeriumiks oli varasem teadaolev paariviljatus rohkem 
kui ühe-aastase perioodi jooksul ning naisepoolsete riskifaktorite puudumine. 
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Peale esmast andmete analüüsi eemaldati uuringust 34 meest puudulike seemne-
vedeliku või vereanalüüside ning varem teostatud väikevaagna piirkonna 
operatsioonide tõttu. Lõplikku uuringugruppi kuulus 164 meest, kes täitsid 
terviseküsimustiku ning kellel teostati seemnevedeliku uuring ja vereanalüüsid 
suguhormoonidele. Kontrollgruppi kaasati uuritavad, kes osalesid uuringus 
“Eesnäärme haigused ja nende omavahelised seosed”, hindasid küsimustiku 
alusel oma tervist heaks ja kinnitasid enda eelnevat teadaolevat bioloogilist 
isadust. Kokku vastas algkriteeriumidele 364 meest, kellest eksklusioonikritee-
riumidele (teadaolevad eelnevad kroonilised ja kasvajalised haigused, operat-
sioonid väikevaagna piirkonnas, munandi laskumishäire ning keemia- ja kiiri-
tusravi, püsiv ravimite tarvitamine ning probleemid paariviljatusega) alusel 
eemaldati 181 meest. Uuritavatest 122 meest keeldus andmast seemnevedeliku 
analüüsi, lõpliku kontrollgrupi moodustasid 61 meest. Kõik uuringus osalenud 
täitsid terviseküsimustiku ning neil teostati seemnevedeliku uuring (WHO, 
1999, 2011) ja vereanalüüsid suguhormoonide määramiseks. 
Keskealiste meeste eesnäärmehaiguste ja reproduktiivfunktsiooni seoste 
uuringusse kaasati algselt 639 meest, kes osalesid uuringus “Eesnäärme haigu-
sed ja nende omavahelised seosed”. Uuringu eksklusioonikriteeriumideks olid 
eelnevalt teadaolevad kasvajalised haigused, operatsioonid ning keemia- ja 
kiiritusravi väikevaagna piirkonnas, munandi laskumishäire(d), probleemid 
paariviljatusega ning eesnäärmekasvajale viitavad muutused eesnäärme palpat-
sioonil. Uuringule eelneva 3 kuu jooksul ei esinenud kellelgi uuringus osale-
nutest uriiniretensiooni ning keegi ei tarvitanud antibiootikume, α1-blokaatoreid 
ja/või 5α-reduktaasi inhibiitoreid. Lõpliku uuringugrupi moodustasid mehed, 
kes olid nõus andma seemnevedeliku analüüsi. Viljakusnäitajate ja mehe sugu-
takti põletiku seoste uuringus osales 382 meest, viljakusnäitajate ja mehe 
alumise kusetrakti kaebuste ning eesnäärme mahu seoste uuringus 422 meest 
ning viljakusnäitajate ja PSA ning eesnäärme histoloogiliste muutuste seoste 
uuringus 377 meest. Uuringuskeemi kuulusid seemnevedeliku analüüs viljakus-
parameetrite ning põletikufooni hindamiseks (WHO, 1999, 2011), vereana-
lüüsid hormoonide ja organ-spetsiifiliste biomarkerite (PSA) määramiseks ning 
eesnäärme funktsionaalsust mõõtvad ultraheli ja kusevoolu kiiruse uuringud. 
Eesnäärme histoloogiline uuring teostati meestel, kelle seerumi PSA väärtus oli 
üle 2,5 ng/ml. Kõik uuritavad täitsid rahvusvahelised eesnäärmehaiguste küsi-
mustikud (NIH-CSPI, I-PSS). 
Uuring teostati SA Tartu Ülikooli Kliinikumi Androloogiakeskuses. Uurin-
gus osalemine oli vabatahtlik. Uuring oli eelnevalt heaks kiidetud Tartu Üli-
kooli Inimuuringute Eetikakomitee poolt (luba 166/T-14, 17.12.2007, 174/T-16, 




Uurimistöö tulemused ja järeldused 
Meie uurimistöö täiendas seniseid keskealiste meeste reproduktiivfunktsiooniga 
seotud teadmisi ning täpsustas eesnäärme mõju mehe reproduktiivfunktsioonile.  
1) Võrreldes tervete keskealiste meeste viljakusnäitajatega esinevad sama-
ealiste viljatute paaride meespartneritel järgnevad olulised erinevused: nais-
suguhormoon östradiooli tase, spermatosoidide üldhulk ja kontsentratsioon 
ning morfoloogiliselt normaalsete spermatosoidide osakaal ja munandimaht 
on viljatute paaride meespartneritel oluliselt madalamad. Selle alusel võib 
järeldada, et viljakusnäitajate langus ei ole seotud ainult vanuselise kom-
ponendiga. 
2) Elustiili küsimustike andmete alusel on regulaarne liikumisaktiivsus kõrgem 
tervetel keskealistel meestel, samas kui viljatute paaride meespartneritel on 
anamneesis rohkem läbipõetud seksuaalsel teel levivaid haigusi. Antud 
seosed tähendavad, et tervislikel eluviisidel on oluline mõju (vananevate) 
meeste viljakusnäitajatele. 
3) Põletikufooni tõus mehe sugutraktis seondub seemnevedeliku koguse ning 
spermide koguarvu ja liikuvuse langusega ning tõstab PSA ja östradiooli 
taset seerumis. Kuna varem on sarnaseid seoseid leitud noortel asümpto-
maatilise suguteede põletikuga meestel, võib meie arvates üheks meeste 
viljakusnäitajaid ja seerumi PSA taset mõjutavaks põhjuseks olla noorte 
meeste eesnäärme ja suguteede põletikest tingitud kahjustus ning põletiku-
fooni hilisem mõju mehe viljakusnäitajatele ja PSA tasemele.    
4) Eesnäärmemahu tõus ja sellega seotud alumise kusetrakti (urineerimis)-
kaebused seonduvad keskealiste meeste viljakusnäitajate langusega. Seega 
ei ole eesnäärme kontroll vajalik mitte ainult urineerimishäirete kontrolli ja 
üldise elukvaliteedi seisukohast, vaid aitab säilitada ja kaudselt jälgida ka 
mehe reproduktiivfunktsiooni.  
5) Premaliigsed ja pahaloomulised eesnäärmepatoloogiad mõjuvad negatiivselt 
mehe seemnevedeliku näitajaid ja tõstavad seerumi FSH taset. Muutused 
võivad lisaks varem kirjeldatud üldtervise, toitumise ja munandi funktsiooni 
mõjudele olla seotud ka eesnäärme kahjustuse ja mehe suguteede (osalise) 
sulgusega.   
6) Seerumi PSA taseme tõus on seotud keskealiste meeste reproduktiiv-
funktsiooni muutustega. Kirjeldatud seos võib tähendada, et subfertiilsed 
ehk langenud viljakusnäitajatega mehed peaksid enda PSA taseme jälgimist 
alustama soovitatavast vanusepiirist varem ning pöörduma PSA tõusu korral 
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